Inca Minerals receives archaeological clearance to progress with project


Published 14-SEP-2016 16:18 P.M.


1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Inca Minerals (ASX:ICG) has been given the go ahead to progress on its zinc-silver-lead Riqueza Project in Peru.

ICG’s Declaracion de Impacto Ambiental drill permit has now been published on the Ministerio de Energia y Minas’ electronic portal.

The archaeological clearance with ICG receiving its Certificate of the Non-Existence of Archaeological Remains (CIRA) signifies a major step forward in the Peruvian permitting process.

ICG is now able to confidently move forward with its exploration plans.

The drill permit application includes an allowance for up to 14,000 metres of drilling on 20 drill platforms and almost 3,000 trenches.

As results are some way off, those looking at ICG as a potential stock for their portfolio should seek professional financial advice.

Ross Brown, Managing Director of ICG said: “Receipt of the CIRA is one of the milestones signalling strong progress with our drill permit application. While there are more (milestones) to achieve, we can aggressively pursue our strategy to find, refine and define drill targets, confident there will be no cultural or archaeological challenges moving forward.”

With its third mapping and sampling exploration complete at Riqueza, further results from ICG’s program are expected to be out within 10-14 days.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free